Levetiracetam Tablet, Extended Release
Product Images NDC 13668-300

9 FDA label images from Torrent Pharmaceuticals Limited · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 13668-300). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Torrent Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (Ectdmodule1usa1)

Image Description (Ectdmodule1usa1)
Chemical structure of levetiracetam, the active ingredient in the drug LEVETIRACETAM. The structure depicts a pyrrolidone ring linked to an ethyl group and an amide functional group.*
FDA Label Image

Image Description (Ectdmodule1usa2)

Image Description (Ectdmodule1usa2)
A bar chart comparing the percentage of patients across three groups: placebo, immediate-release levetiracetam 1000 mg/day, and immediate-release levetiracetam 3000 mg/day. The chart shows patient percentages on the y-axis and treatment groups on the x-axis, with higher percentages for the levetiracetam groups compared to placebo.*
FDA Label Image

Image Description (Ectdmodule1usa3)

Image Description (Ectdmodule1usa3)
A bar graph displaying percentages of patients across three groups: Placebo (6.3%), Immediate-release Levetiracetam 1000 mg/day (20.8%), and Immediate-release Levetiracetam 2000 mg/day (35.2%). The x-axis shows treatment groups with sample sizes, and the y-axis represents percentage of patients from 0% to 45%.*
FDA Label Image

Image Description (Ectdmodule1usa4)

Image Description (Ectdmodule1usa4)
A bar chart comparing the percentage of patients between two groups: Placebo (N=104) with 14.4% and Immediate-release Levetiracetam 3000 mg/day (N=180) with 39.4%. The y-axis represents the percentage of patients, ranging from 0% to 45%.*
FDA Label Image

Image Description (Ectdmodule1usa5)

Image Description (Ectdmodule1usa5)
A bar graph comparing the percentage of patients between two groups: Placebo (N=97) and Immediate-release Levetiracetam (N=101). The graph shows approximately 19.6% for the placebo group and 44.6% for the immediate-release levetiracetam group along the y-axis labeled '% of Patients.'*
FDA Label Image

Logo (Logo Pi)

FDA Label Image

Logo-mg (Logo mg)

FDA Label Image

500mg (500mg)

FDA Label Image

750mg (750mg)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.